TY - JOUR T1 - Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity JF - Journal of Investigative Medicine JO - J Investig Med SP - 3 LP - 4 DO - 10.1136/jim-2021-002227 VL - 70 IS - 1 AU - Ricardo Villela AU - Ricardo Correa Y1 - 2022/01/01 UR - http://hw-f5-jim.highwire.org/content/70/1/3.abstract N2 - Overweight and obesity are one of the most relevant health factors; according to the WHO, 39% of people globally are overweight and 13% obese.1 Body weight loss of 3%–5% has been linked to a reduction in risk factors, whereas those with obesity and chronic illness should lose 5%–15% of their body weight to reduce risks.2 Glucose lowering medications, particularly glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs), might result in considerable weight loss.3 Semaglutide 2.4 mg (brand name Wegovy) was recently authorized by the Food and Drug Administration for chronic weight management. It is indicated in patients with a body mass index (BMI)≥30 kg/m2, or a BMI≥27 kg/m2 with comorbidities.4 The STEPs studies were the … ER -